title: Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).
abstract: The introduction of immunotherapeutic agents has provided renewed hope for Chronic lymphocytic leukemia fludarabine-refractory patients. Several clinical trials have shown that alemtuzumab is a more effective option compared to combination chemotherapy for treatment of patients who have relapsed or who are refractory to fludarabine, including those with poor prognostic factors. Although there are significant potential toxicities associated with alemtuzumab, such as infusional reactions and the risk of cytomegalovirus (CMV) reactivation, most are manageable. Pre-treatment anti-pyretics and anti-histamines are recommended to prevent or mitigate the acute infusional reactions associated with intravenous infusion. Recent use of alemtuzumab via the subcutaneous route has been shown to be well tolerated and has yielded similar response rates to the infusional method of administration. Prophylaxis with thrimethoprim/sulphamethoxazole (TMP/SMZ) as well as valacyclovir or a similar anti-viral can prevent many of the opportunistic infections seen in early trials. Reactivation of CMV infection can be effectively managed with monitoring and early treatment. Chemo-immunotherapy combination with alemtuzumab has been tested and demonstrated unprecedented clinical results in relapsed and refractory patients. The use of this agent earlier in the algorithm of patients with these characteristics should be considered. Future areas of research will include the use of alemtuzumab in combination with other monoclonal antibodies and other targeted therapies.
authors.affiliation: Department of Oncology/Hematology, Division of Hematology and Bone Marrow Transplant Unit, Niguarda Ca' Granda Hospital, Milan, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Montillo
authors.forename: Francesca
authors.initials: F
authors.lastname: Ricci
authors.forename: Sara
authors.initials: S
authors.lastname: Miqueleiz
authors.forename: Alessandra
authors.initials: A
authors.lastname: Tedeschi
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
references.citation: Blood. 2004 Aug 15;104(4):948-55
references.pmid: 15090452
references.citation: Blood. 2002 Mar 15;99(6):2245-7
references.pmid: 11877305
references.citation: Immunology. 1998 Nov;95(3):427-36
references.pmid: 9824507
references.citation: N Engl J Med. 1994 Feb 3;330(5):319-22
references.pmid: 7904047
references.citation: Blood. 1995 Mar 15;85(6):1580-9
references.pmid: 7888675
references.citation: Br J Haematol. 1986 Nov;64(3):479-86
references.pmid: 3539172
references.citation: Semin Oncol. 2002 Feb;29(1 Suppl 2):75-80
references.pmid: 11842392
references.citation: Lancet. 2007 Jul 21;370(9583):230-239
references.pmid: 17658394
references.citation: Haematologica. 2005 Oct;90(10):1435-6
references.pmid: 16219582
references.citation: Blood. 2002 Aug 1;100(3):768-73
references.pmid: 12130484
references.citation: Blood. 2004 Aug 1;104(3):655-8
references.pmid: 15073032
references.citation: Leukemia. 2004 Jun;18(6):1093-101
references.pmid: 15071604
references.citation: Leuk Lymphoma. 2004 Nov;45(11):2269-73
references.pmid: 15512816
references.citation: Hematol J. 2001;2(5):300-6
references.pmid: 11920265
references.citation: N Engl J Med. 2003 Dec 25;349(26):2570-2; discussion 2570-2
references.pmid: 14695424
references.citation: N Engl J Med. 2000 Dec 14;343(24):1750-7
references.pmid: 11114313
references.citation: J Clin Oncol. 2005 May 1;23(13):2971-9
references.pmid: 15738539
references.citation: J Clin Oncol. 1997 Apr;15(4):1567-74
references.pmid: 9193354
references.citation: Cancer. 1974 Feb;33(2):555-62
references.pmid: 4812772
references.citation: Leukemia. 2006 Aug;20(8):1441-5
references.pmid: 16738694
references.citation: J Clin Oncol. 2005 Oct 1;23(28):7024-31
references.pmid: 16145065
references.citation: Clin Lymphoma. 2002 Sep;3(2):105-10
references.pmid: 12435283
references.citation: Haematologica. 2005 Mar;90(3):410-2
references.pmid: 15749678
references.citation: N Engl J Med. 1992 Oct 8;327(15):1056-61
references.pmid: 1355853
references.citation: Clin Lymphoma. 2004 Mar;4(4):220-7
references.pmid: 15072613
references.citation: N Engl J Med. 1993 Mar 18;328(11):812-3
references.pmid: 8094889
references.citation: J Clin Oncol. 2002 Sep 15;20(18):3891-7
references.pmid: 12228210
references.citation: Blood. 2002 May 15;99(10):3554-61
references.pmid: 11986207
references.citation: Blood. 1993 Jun 1;81(11):2878-84
references.pmid: 8499626
references.citation: Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30
references.pmid: 17026823
references.citation: Eur J Immunol. 1993 May;23(5):1098-104
references.pmid: 8477804
references.citation: Leuk Lymphoma. 2002 May;43(5):1007-11
references.pmid: 12148879
references.citation: Med Oncol. 2002;19 Suppl:S11-9
references.pmid: 12180487
references.citation: Blood. 1996 Jun 15;87(12):4990-7
references.pmid: 8652811
references.citation: Blood. 2006 Feb 1;107(3):885-91
references.pmid: 16219797
references.citation: Leuk Lymphoma. 2002 Sep;43(9):1755-62
references.pmid: 12685828
references.citation: J Clin Oncol. 1985 Sep;3(9):1196-201
references.pmid: 2993534
references.citation: Leuk Lymphoma. 1993;10 Suppl:43-9
references.pmid: 8097654
references.citation: Cancer Treat Rep. 1979 Mar;63(3):441-7
references.pmid: 371799
references.citation: Lancet. 1996 May 25;347(9013):1432-8
references.pmid: 8676625
references.citation: Blood. 1993 Aug 1;82(3):807-12
references.pmid: 7687895
references.citation: Cancer. 2003 Aug 15;98(4):773-8
references.pmid: 12910522
references.citation: Blood. 2003 May 1;101(9):3413-5
references.pmid: 12522009
references.citation: J Clin Oncol. 2007 Mar 1;25(7):793-8
references.pmid: 17283364
references.citation: Hematology Am Soc Hematol Educ Program. 2004;:163-83
references.pmid: 15561682
references.citation: Blood. 2001 Oct 15;98(8):2319-25
references.pmid: 11588025
references.citation: Blood. 1989 Jul;74(1):19-25
references.pmid: 2473795
references.citation: Blood. 2004 May 1;103(9):3278-81
references.pmid: 14726385
references.citation: N Engl J Med. 2002 Aug 8;347(6):452-3
references.pmid: 12167696